AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
出版年份 2012 全文链接
标题
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
作者
关键词
-
出版物
CANCER
Volume 118, Issue 24, Pages 6152-6161
出版商
Wiley
发表日期
2012-06-13
DOI
10.1002/cncr.27632
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)
- (2017) J. A. Sosman et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).
- (2017) A. J. Bullock et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
- (2011) J. Beck et al. ANNALS OF ONCOLOGY
- Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
- (2011) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating biomarkers of bevacizumab activity in patients with breast cancer
- (2010) Neelima Denduluri et al. CANCER BIOLOGY & THERAPY
- New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance
- (2010) B. I. Rini CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
- (2010) Michael B. Bass et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
- (2010) A. Coxon et al. MOLECULAR CANCER THERAPEUTICS
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
- (2009) J. Baar et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started